RPS Conference 2010, Abstracts 2010 - Royal Pharmaceutical Society

More documents

Recommendations

Info

students felt pharmacists deserved to earn more than nurses. Students were unsure how funding would be organised in the future with 73% agreeing it should be from clinical services. Many (79.3%, missing=3) believed that these professional changes may not be possible due to commercial pressures and were concerned about the corporatisation of community pharmacy. 81.6% (n=49) agreed that their degree prepared them for future community pharmacy practice. Conclusions Most students showed optimism about pharmacists’ future clinical role in healthcare. The high degree of variation in responses is suggestive of an uncertain future. Further research with a larger sample size needs to be carried out to explore student perceptions, as their beliefs will have a large influence on future professional practice. References [1] Department of Health. (2008) Pharmacy in England: building on strengths – delivering the future. (Cm 7341). London: The Stationary Office. [2] Taylor, D. and Carter, S. (2002) Realising the promise – community pharmacy in the new NHS. London: The school of pharmacy, University of London.
79 Linkage of routinely collected NHS data to create a paediatric pharmacovigilance database: opinions of national stake holders Yvonne Hopf 1,2 , Christine Bond 1 , John Haughney 1 , Peter Helms 2 1 Centre of Academic Primary Care, University of Aberdeen, Aberdeen, United Kingdom, 2 Department of Child Health, University of Aberdeen, Aberdeen, United Kingdom Focal Points: • The study aim is to assess national stakeholders’ opinions of and attitudes to the linking of routinely acquired NHS data as a means of identifying adverse drug reactions (ADRs) in children. • Preliminary findings show practical and legal issues with data linkage as well as a need for public involvement. • The creation of said database is received as beneficial but several concerns have been raised that will need to be addressed. Introduction Paediatric pharmacovigilance is a recognised priority. There is widespread use of medicines offlabel in children and a recognised vulnerability to adverse drug reactions (ADRs) 1,2 . The introduction of the community health index (CHI) in all NHS contacts in Scotland provides opportunities to link data and opportunities to identify ADRs by linking prescribing and health utilization data. A large NHS Applied Research Programme Grant - Pharmacovigilance for children: Signal generation from linked NHS administrative data -funded by the Chief Scientist Office- is exploring the feasibility of constructing a database of linked routinely collected data for the purposes of paediatric pharmacovigilance. Assessing the acceptability is important so that solutions can be tailored to address concerns. The aim is to gather the opinion and attitudes of health care professionals to the linkage of routinely collected paediatric data for pharmacovigilance purposes in Scotland and to identify concerns, if any, before said database is created. Method Ethically approved semi-structured interviews are being used to capture views on pharmacovigilance, confidentiality/patient privacy, data protection, acceptable and nonacceptable usage of data and their dissemination. The sample has been purposively designed and includes national experts on these topics plus REC chairs and Caldicott guardians from all Scottish Health Boards. All interviews are audio-recorded and fully transcribed. A framework approach is used to identify themes inductively, but the researcher is open for emergent themes. Results Preliminary findings of the early interviews (n=15) have shown that current schemes are perceived as being limited: “it [spontaneously reporting] doesn’t produce data, it produces anecdotes” (interview A04). The creation of the proposed database has raised concerns about data linkage at both practical and legal levels. Practical points included the logistics of the data linkage and the usability of hospital data. Legal issues centre on data protection and consent. Data access will have to be clearly defined and controlled. A need has been recognised for the public to be to be fully informed of the research, its purpose and emergent results. Concerns have been expressed about the possible use of the data for audits and its potential to call the performance of health professionals into question rather than increasing the safety and efficacy
Page 1 and 2:
1 Cost effectiveness of community p
Page 3 and 4:
2 The Diabetes Pilot Program: Barri
Page 5 and 6:
3 The PINCER trial: a cluster rando
Page 7 and 8:
4 How pharmacists working on the PI
Page 9 and 10:
5 A systematic review of weight man
Page 11 and 12:
6 An exploration of the potential i
Page 13 and 14:
7 An Exploration of Nursing Home Ma
Page 15 and 16:
8 Unintended discrepancies between
Page 17 and 18:
9 Unlicensed Medicines: Risk and Re
Page 19 and 20:
10 Audit of Discharge Summaries in
Page 21 and 22:
11 Over-the-counter simvastatin: co
Page 23 and 24:
12 A qualitative study of disadvant
Page 25 and 26:
13 Pharmacist prescribing in North
Page 27 and 28:
14 Pharmacist prescribing in primar
Page 29 and 30:
15 Training undergraduate pharmacy
Page 31 and 32:
16 ‘You’re an agent unto yourse
Page 33 and 34:
17 Information for young people wit
Page 35 and 36:
18 The Role of the Pharmacist and E
Page 37 and 38:
19 Exploring patient opinions of MU
Page 39 and 40:
20 Why do patients accept or declin
Page 41 and 42:
21 Further investigations on GP pre
Page 43 and 44:
22 The HAPPY trial: a randomised co
Page 45 and 46:
23 The effects of numeracy on the p
Page 47 and 48:
24 Translation and evaluation of
Page 49 and 50:
25 Influence of relationships, trus
Page 51 and 52:
26 Title: Pharmacists’ well being
Page 53 and 54:
27 What do newly qualified pharmaci
Page 55 and 56:
28 Does learning the “pure” sci
Page 57 and 58:
29 Defining and identifying perform
Page 59 and 60:
30 Engendering and Appraising ‘Pr
Page 61 and 62:
31 Inappropriate prescribing of Opi
Page 63 and 64:
32 Developing a five-year curriculu
Page 65 and 66:
33 An Investigation of the incidenc
Page 67 and 68:
34 Analysing medicine wastage in th
Page 69 and 70:
35 A Clinical Audit on the Use of A
Page 71 and 72:
36 A Clinical Audit on Reporting an
Page 73 and 74:
37 Assessment of hypertension care
Page 75 and 76:
38 Community pharmacy EHC services:
Page 77 and 78:
39 The Impact of the Lloyds Pharmac
Page 79 and 80:
40 Medication and handover incident
Page 81 and 82:
41 The time-scale for delivery of p
Page 83 and 84:
42 Medication access in primary car
Page 85 and 86:
43 A solution to improving uptake o
Page 87 and 88:
44 Medicines Information to Support
Page 89 and 90:
45 Are pharmacist public health pra
Page 91 and 92:
46 Anticoagulation for haemofiltrat
Page 93 and 94:
47 Med Wreck: An Audit of Communica
Page 95 and 96:
48 Pandemic flu preparedness: Plann
Page 97 and 98:
49 Young people's views about chlam
Page 99 and 100:
50 Psychotropic use in elderly pati
Page 101 and 102:
51 Using simulation of community ph
Page 103 and 104:
52 ‘Pharmacists in Schools’: De
Page 105 and 106: 53 What do Pharmacists in Surrey wa
Page 107 and 108: 54 Has the new audit module in the
Page 109 and 110: 55 Introduction of a Nursing Home B
Page 111 and 112: 56 An audit of Benzodiazepine presc
Page 113 and 114: 57 Improving patient safety through
Page 115 and 116: 58 Video clips enhance student lear
Page 117 and 118: 59 Do preregistration trainee pharm
Page 119 and 120: 60 An investigation of the views of
Page 121 and 122: 61 Ensuring accuracy in routinely c
Page 123 and 124: 62 Deprivation status and utilizati
Page 125 and 126: 63 Exploring Reasons, Factors and A
Page 127 and 128: 64 I’m off to the gym: Exploring
Page 129 and 130: 65 Is there alignment between the v
Page 131 and 132: 66 The views of out-patients with c
Page 133 and 134: 67 Patient Experiences of Living wi
Page 135 and 136: 68 Clinical management and cost of
Page 137 and 138: 69 Medicines Use Reviews - how have
Page 139 and 140: 70 How are pharmacists, registered
Page 141 and 142: 71 Barriers facing hypertensive pat
Page 143 and 144: 72 Developing an RCT of general pra
Page 145 and 146: 73 User and Staff Perspectives of C
Page 147 and 148: 74 Impact of pandemic influenza A/H
Page 149 and 150: 75 How do patients with osteoporosi
Page 151 and 152: 76 Integrating tuberculosis and dia
Page 153 and 154: 77 Improving outcomes and quality o
Page 155: 78 The uncertain future: a pilot st
Page 159 and 160: 80 Impact of Formative Assessment o
Page 161 and 162: 81 The prevalence of pharmacists’
Page 163 and 164: 82 A comparative study of prescribi
Page 165 and 166: 83 Evaluation of patient informatio
Page 167 and 168: 84 Patient medication adherence: a
Page 169 and 170: 85 Fitness to practise: pharmacists
Page 171 and 172: 86 Measurement of empathy levels in
Page 173 and 174: 87 Benzyl Alcohol Exposure from Hep
Page 175 and 176: 88 Neonatal gentamicin infusions- W
Page 177 and 178: 89 Unlicensed and off-label use of
Page 179 and 180: 90 Unlicensed and off-label prescri
Page 181 and 182: 91 Exploring community pharmacists
Page 183 and 184: 92 Investigation into Rapid Microbi
Page 185 and 186: 93 Pharmacy prescribing in XXXX-a q
Page 187 and 188: 94 Pharmacy prescribing in XXXX-a q
Page 189 and 190: 95 MEDICINE RELATED PROBLEMS IN SOU
Page 191 and 192: 96 Stability of pharmaceutical prod
Page 193 and 194: 97 The experiences of Malaysian pha
Page 195 and 196: 98 Medication management in older p
Page 197 and 198: 99 Adherence with calcium and vitam
Page 199 and 200: 100 Appraisal systems within commun
Page 201 and 202: 101 The clinical impact of a fractu
Page 203 and 204: 102 An audit of primary care prescr
Page 205 and 206: 103 Views of the public on over-the
show all

RPS Conference 2010, Abstracts 2010 - Royal Pharmaceutical Society

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?